nach oben

Current Hypertension Reports

Erschienen in:

01.02.2018 | Hypertension and the Brain (R Wainford, Section Editor)

Vasopressin, Central Autonomic Control and Blood Pressure Regulation

verfasst von: Maja Lozić, Olivera Šarenac, David Murphy, Nina Japundžić-Žigon

Erschienen in: Current Hypertension Reports | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

We present recent advances in understanding of the role of vasopressin as a neurotransmitter in autonomic nervous system control of the circulation, emphasizing hypothalamic mechanisms in the paraventricular nucleus (PVN) involved in controlling sympathetic outflow toward the cardiovascular system.

Recent Findings

Suggest that somato-dendritically released vasopressin modulates the activity of magnocellular neurons in the PVN and SON, their discharge pattern and systemic release. Advances have been made in uncovering autocrine and paracrine mechanisms controlling presympathetic neuron activity, involving intranuclear receptors, co-released neuroactive substances and glia.

Summary

It is now obvious that intranuclear release of vasopressin and the co-release of neuroactive substances in the PVN, as well as the level of expression of vasopressin receptors, modulate sympathetic outflow to the cardiovascular system and determine vulnerability to stress. Further research involving patho-physiological models is needed to validate these targets and foster the development of more efficient treatment.

World Health Organization: A global brief on Hypertension 2013.

Japundžić-Žigon N. Vasopressin and oxytocin in control of the cardiovascular system. Curr Neuropharmacol. 2013;11(2):218–30. https://doi.org/10.2174/1570159X11311020008.CrossRefPubMedPubMedCentral

Dampney RAL, Coleman MJ, Fontes MA, Hirooka Y, Horiuchi J, Li Y-W, et al. Central mechanisms underlying short- and long-term regulation of the cardiovascular system. Clin Exp Pharmacol Physiol. 2002;29:261–8.CrossRefPubMed

Dampney RAL. Central neural control of the cardiovascular system: current perspectives. Adv Physiol Educ. 2016;40:283–96.CrossRefPubMed

Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7(5):335–46. https://doi.org/10.1038/nrn1902.CrossRefPubMed

Carmichael CY, Wainford RD. Hypothalamic signaling mechanisms in hypertension. Curr Hypertens Rep. 2015;17:39.CrossRefPubMedPubMedCentral

DiBona GF. Sympathetic nervous system and hypertension. Hypertension. 2013;61(3):556–60. https://doi.org/10.1161/HYPERTENSIONAHA.111.00633.CrossRefPubMed

Parati G, Elser M. The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J. 2012;33(9):1058–66. https://doi.org/10.1093/eurheartj/ehs041.CrossRefPubMed

Burbach JP, Luckman SM, Murphy D, Gainer H. Gene regulation in the magnocellular hypothalamo-neurohypophysial system. Physiol Rev. 2001;81(3):1197–267. https://doi.org/10.1152/physrev.2001.81.3.1197.CrossRefPubMed

10.

Pyner S. Neurochemistry of the paraventricular nucleus of the hypothalamus: implications for cardiovascular regulation. J Chem Neuroanat. 2009;38:197–208.CrossRefPubMed

11.

Pyner S, Guyenet GP. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335–46.

12.

Pyner S, Coote JH. Identification of an efferent projection from the paraventricular nucleus of the hypothalamus terminating close to spinally projecting rostral ventrolateral medullary neurons. Neuroscience. 1999;88(3):949–57. https://doi.org/10.1016/S0306-4522(98)00255-3.CrossRefPubMed

13.

Pyner S, Coote JH. Identification of branching paraventricular neurons of the hypothalamus that project to the rostroventrolateral medulla and spinal cord. Neuroscience. 2000;100(3):549–56. https://doi.org/10.1016/S0306-4522(00)00283-9.CrossRefPubMed

14.

Hallbeck M, Blomqvist A. Spinal cord-projecting vasopressinergic neurons in the rat paraventricular hypothalamus. J Comp Neurol. 1999;411(2):201–11. https://doi.org/10.1002/(SICI)1096-9861(19990823)411:2<201::AID-CNE3>3.0.CO;2-3.CrossRefPubMed

15.

Koshimizu T, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92(4):1813–64. https://doi.org/10.1152/physrev.00035.2011.CrossRefPubMed

16.

Kato Y, Igarashi N, Hirasawa A, Tsujimoto G, Kobayashi M. Distribution and developmental changes in vasopressin V2 receptor mRNA in rat brain. Differentiation. 1995;59(3):163–9. https://doi.org/10.1046/j.1432-0436.1995.5930163.x.CrossRefPubMed

17.

Milutinović-Smiljanić S, Šarenac O, Lozić-Djurić M, Murphy D, Japundžić-Žigon N. Evidence for involvement of central vasopressin V1b and V2 receptors in stress-induced baroreflex desensitization. Br J Pharmacol. 2013;169(4):900–8. https://doi.org/10.1111/bph.12161.CrossRefPubMedPubMedCentral

18.

Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl AcadSci U S A. 2006;103(20):7807–12. https://doi.org/10.1073/pnas.0600875103.CrossRef

19.

Berecek KH, Webb RL, Barron KW, Brody MJ. Vasopressin projections and central control of cardiovascular function. Ann N Y Acad Sci. 1982;394(1 The Brattlebo):729–34. https://doi.org/10.1111/j.1749-6632.1982.tb37490.x.CrossRefPubMed

20.

Ostrowski NL, Lolait SJ, Bradley DJ, O'Carroll AM, Brownstein MJ, Young WS 3rd. Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain. Endocrinology. 1992;131(1):533–5. https://doi.org/10.1210/endo.131.1.1535312.CrossRefPubMed

21.

Barberis C, Tribollet E. Vasopressin and oxytocin receptors in the central nervous system. Crit Rev Neurobiol. 1996;10(1):119–54.CrossRefPubMed

22.

Gerstberger R, Fahrenholz F. Autoradiographic localization of V1 vasopressin binding sites in rat brain and kidney. Eur J Pharmacol. 1989;167(1):105–16. https://doi.org/10.1016/0014-2999(89)90752-8.CrossRefPubMed

23.

Sermasi E, Howl J, Wheatley M, Coote JH. Localisation of arginine vasopressin V1a receptors on sympatho-adrenal preganglionic neurones. Exp Brain Res. 1998;119(1):85–91. https://doi.org/10.1007/s002210050322.CrossRefPubMed

24.

Tribollet E, Barberis C, Arsenijevic Y. Distribution of vasopressin and oxytocin receptors in the rat spinal cord: sex-related differences and effect of castration in pudendal motor nuclei. Neuroscience. 1997;78(2):499–509. https://doi.org/10.1016/S0306-4522(96)00591-X.CrossRefPubMed

25.

Martin SM, Malkinson TJ, Veale WL, Pittman QJ. The action of centrally administered arginine vasopressin on blood pressure in the conscious rabbit. Brain Res. 1985;348(1):137–45. https://doi.org/10.1016/0006-8993(85)90369-5.CrossRefPubMed

26.

• Han SY, Bouwer GT, Seymour AJ, Korpal AK, Schwenke DO, Brown CH. Induction of hypertension blunts baroreflex inhibition of vasopressin neurons in the rat. Eur J Neurosci. 2015;42(9):2690–8. Centrally injected angiotensin II increases the firing rate of magnocellular neurons, and that this increase was not related to the changes in plasma osmolality, but rather to a decrease in baroreflex inhibition of vasopressin neurons.CrossRefPubMed

27.

Son SJ, Filosa JA, Potapenko ES, Biancardi VC, Zheng H, Patel KP, et al. Dendritic peptide release mediates interpopulation crosstalk between neurosecretory and preautonomic networks. Neuron. 2013;78(6):1036–49. https://doi.org/10.1016/j.neuron.2013.04.025.CrossRefPubMed

28.

• Ribeiro N, do Nascimento Panizza H, dos Santos KM, Ferreira-Neto HC, Antunes VR. Salt-induced sympathoexcitation involves vasopressin V1a receptor activation in the paraventricular nucleus of the hypothalamus. Am J Physiol Regul Integr Comp Physiol. 2015;309:R1369–79. The consumption of a high salt diet induces sympatho-exitation and high blood pressure via the action of vasopressin on V1aRs in the PVN.CrossRefPubMed

29.

• Lozic M, Tasic T, Martin A, Greenwood M, Sarenac O, Hindmarch C, et al. Over-expression of V1a receptors in PVN modulates autonomic cardiovascular control. Pharmacol Res. 2016;114:185–95. Virally mediated overexpression of V1aRs in the PVN reduces baroreceptor sensitivity under baseline conditions, and increase BP and HR variability during exposure to stress, indicating that V1aRs in the PVN influences autonomic cardiovascular regulation and demarcate vulnerability to stress.CrossRefPubMed

30.

Rossi NF, Maliszewska-Scislo M. Role of paraventricular nucleus vasopressin V1A receptors in the response to endothelin 1 activation of the subfornical organ in the rat. J Physiol Pharmacol. 2008;59(Suppl 8):47–5.PubMedPubMedCentral

31.

Japundžić-Žigon N, Šarenac O, Lozić M, Vasić M, Tasić T, Bajić D, et al. Sudden death: neurogenic causes, prediction and prevention. Eur J Prev Cardiol. 2017;25(1):2047487317736827–39. https://doi.org/10.1177/2047487317736827.

32.

Oikawa R, Hosoda C, Nasa Y, Daicho T, Tanoue A, Tsujimoto G, et al. Decreased susceptibility to salt-induced hypertension in subtotally nephrectomized mice lacking the vasopressin V1a receptor. Cardiovasc Res. 2010;87(1):187–94.CrossRefPubMed

33.

Fujiwara Y, Tanoue A, Tsujimoto G, Koshimizu TA. The roles of V1a vasopressin receptors in blood pressure homeostasis: a review of studies on V1a receptor knockout mice. Clin Exp Nephrol. 2012;16(1):30–4. https://doi.org/10.1007/s10157-011-0497-y.CrossRefPubMed

34.

Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A. 2006;103(20):7807–12.CrossRefPubMedPubMedCentral

35.

Gouzènes L, Desarménien MG, Hussy N, Richard P, Moos FC. Vasopressin regularizes the phasic firing pattern of rat hypothalamic magnocellular vasopressin neurons. J Neurosci. 1998;18(5):1879–85.PubMed

36.

Ludwig M, Leng G. Dendritic peptide release and peptide-dependent behaviours. Nat Rev Neurosci. 2006;7(2):126–36. https://doi.org/10.1038/nrn1845.CrossRefPubMed

37.

Tobin V, Leng G, Ludwig M. The involvement of actin, calcium channels and exocytosis proteins in somato-dendritic oxytocin and vasopressin release. Front Physiol. 2012;3:261.CrossRefPubMedPubMedCentral

38.

Lombardi F. Clinical implications of present physiological understanding of HRV components. Card Electrophysiol Rev. 2002;6:245–9.CrossRefPubMed

39.

Narkiewicz K, Grassi G. Impaired baroreflex sensitivity as a potential marker of cardiovascular risk in hypertension. J Hypertens. 2008;26(7):1303–4. https://doi.org/10.1097/HJH.0b013e328305e1a5.CrossRefPubMed

40.

Parati G, Ochoa JE, Bilo G. Blood pressure variability, cardiovascular risk, and risk for renal disease progression. Curr Hypertens Rep. 2012;14:421–31.CrossRefPubMed

41.

Jackiewicz E, Szczepanska-Sadowska E, Dobruch J. Altered expression of angiotensin at1a and vasopressinv1a receptors and nitric oxide synthase mRNA in the brain of rats with renovascular hypertension. J Physiol Pharmacol. 2004;55(4):725–37.PubMed

42.

God A, Malinski W, Kumosa M, Dobruch J, Szczepanska-Sadowska E. Differential expression of vasopressin V1a and V1b receptors mRNA in the brain of renin transgenic TGRmRen2 (27) and Sprague Dawley rats. Brain Res Bull. 2003;59:399–403.CrossRef

43.

McDougall J, Roulston CA, Widdop RE, Lawrence AJ. Characterisation of vasopressin V1A, angiotensin AT1 and AT2 receptor distribution and density in normotensive and hypertensive rat brain stem and kidney: effects of restraint stress. Brain Res. 2000;883(1):148–56.CrossRefPubMed

44.

Volpi S, Rabadan-Diehl C, Aguilera G. Vasopressinergic regulation of the hypothalamic pituitary adrenal axis and stress adaptation. Stress. 2004;7(2):75–83. https://doi.org/10.1080/10253890410001733535.CrossRefPubMed

45.

Litvin Y, Murakami G, Pfaff DW. Effects of chronic social defeat on behavioral and neural correlates of sociality: Vasopressin, oxytocin and the vasopressinergic V1b receptor. Physiol Behav. 2011;103(3–4):393–403.CrossRefPubMed

46.

Vaccari C, Lolait SJ, Ostrowski NL. Comparative distribution of vasopressin V1b and oxytocin receptor messenger ribonucleic acids in brain. Endocrinology. 1998;139(12):5015–33. https://doi.org/10.1210/endo.139.12.6382.CrossRefPubMed

47.

Hernando F, Schoots O, Lolait SJ, Burbach JP. Immunohistochemical localization of the vasopressin V1b receptor in the rat brain and pituitary gland: anatomical support for its involvement in the central effects of vasopressin. Endocrinology. 2001;142(4):1659–68. https://doi.org/10.1210/endo.142.4.8067.CrossRefPubMed

48.

Wersinger SR, Ginns EI, O’Carroll AM, Lolait SJ, Young WS 3rd. Vasopressin V1b receptor knockout reduces aggressive behavior in male mice. Mol Psychiatry. 2002;7(9):975–84. https://doi.org/10.1038/sj.mp.4001195.CrossRefPubMed

49.

Caldwell HK, Dike OE, Stevenson EL, Storck K, Young WS 3rd. Social dominance in male vasopressin 1b receptor knockout mice. Horm Behav. 2010;58(2):257–63.CrossRefPubMedPubMedCentral

50.

Blanchard RJ, Griebel G, Farrokhi C, Markham C, Yang M, Blanchard DC. AVP V1b selective antagonist SSR149415 blocks aggressive behaviors in hamsters. Pharmacol Biochem Behav. 2005;80(1):189–94.CrossRefPubMed

51.

Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, et al. Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders. Proc Natl Acad Sci U S A. 2002;99(9):6370–5. https://doi.org/10.1073/pnas.092012099.CrossRefPubMedPubMedCentral

52.

Iijima M, Yoshimizu T, Shimazaki T, Tokugawa K, Fukumoto K, Kurosu S, et al. Antidepressant and anxiolytic profiles of newly synthesized arginine vasopressin V1B receptor antagonists: TASP0233278 and TASP0390325. Br J Pharmacol. 2014;171(14):3511–25.CrossRefPubMedPubMedCentral

53.

Brunner SM, Farzi A, Locker F, Holub BS, Drexel M, Reichmann F, et al. GAL3 receptor KO mice exhibit an anxiety-like phenotype. Proc Natl AcadSci U S A. 2014;111(19):7138–43. https://doi.org/10.1073/pnas.1318066111.CrossRef

54.

El-Werfali W, Toomasian C, Maliszewska-Scislo M, Li C, Rossi NF. Haemodynamic and renal sympathetic responses to V1b vasopressin receptor activation within the paraventricular nucleus. Exp Physiol. 2015;100(5):553–65.CrossRefPubMed

55.

Reaux A, De Mota N, Skultetyova I, Lenkei Z, El Messari S, Gallatz K, et al. Physiological role of a novel neuropeptide, apelin, and its receptor in the rat brain. J Neurochem. 2001;77(4):1085–96. https://doi.org/10.1046/j.1471-4159.2001.00320.x.CrossRefPubMed

56.

O’Carroll A-M, Lolait SJ. Regulation of rat APJ receptor messenger ribonucleic acid expression in magnocellular neurones of the paraventricular and supraoptic nuclei by osmotic stimuli. J Neuroendocrinol. 2003;15(7):661–6. https://doi.org/10.1046/j.1365-2826.2003.01044.x.CrossRefPubMed

57.

Brown CH, Ruan M, Scott V, Tobin VA, Ludwig M. Multi-factorial somato-dendritic regulation of phasic spike discharge in vasopressin neurons. Prog Brain Res. 2008;170:219–28. https://doi.org/10.1016/S0079-6123(08)00419-6.CrossRefPubMed

58.

Zhang Q, Yao F, Raizada MK, O’Rourke ST, Sun C. Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res. 2009;104(12):1421–8. https://doi.org/10.1161/CIRCRESAHA.108.192302.CrossRefPubMedPubMedCentral

59.

Zhang F, Sun H-J, Xiong X-Q, Chen Q, Li Y-H, Kang Y-M, et al. Apelin-13 and APJ in paraventricular nucleus contribute to hypertension via sympathetic activation and vasopressin release in SHR. Acta Physiol. 2014;212:17–27.CrossRef

60.

Kagiyama S, Fukuhara M, Matsumura K, Lin Y, Fujii K, Iida M. Central and peripheral cardiovascular actions of apelin in conscious rats. Regul Pept. 2005;125:55–9.CrossRefPubMed

61.

Reaux-Le Goazigo A, Morinville A, Burlet A, Llorens-Cortes C, Beaudet A. Dehydration-induced cross-regulation of apelin and vasopressin immunoreactivity levels in magnocellular hypothalamic neurons. Endocrinology. 2004;14:4392–400.CrossRef

62.

• Griffiths PR, Lolait SJ, Harris LE, Paton JFR, O’Carroll A-M. Vasopressin V1a receptors mediate the hypertensive effects of [PYR1]apelin-13 in the rat rostral ventrolateral medulla. J Physiol. 2017;595(11):3303–18. Apelin-induced sympatho-excitation at the level of RVLM is dependent upon V1aRs.CrossRefPubMedPubMedCentral

63.

Shen XZ, Li Y, Li L, Shah KH, Bernstein KE, Lyden P, et al. Microglia participate in neurogenic regulation of hypertension. Hypertension. 2015;66(2):309–16. https://doi.org/10.1161/HYPERTENSIONAHA.115.05333.CrossRefPubMedPubMedCentral

64.

Potapenko ES, Biancardi VC, Zhou Y, Stern JE. Altered astrocyte glutamate transporter regulation of hypothalamic neurosecretory neurons in heart failure rats. Am J Physiol Regul Integr Comp Physiol. 2012;303(3):R291–300. https://doi.org/10.1152/ajpregu.00056.2012.CrossRefPubMedPubMedCentral

65.

Stern JE, Son S, Biancardi VC, Zheng H, Sharma N, Patel KP. Astrocytes contribute to angiotensin II stimulation of hypothalamic neuronal activity and sympathetic outflow. Hypertension. 2016;68(6):1483–93. https://doi.org/10.1161/HYPERTENSIONAHA.116.07747.CrossRefPubMedPubMedCentral

66.

Zhang M, Stern JE. Altered NMDA receptor-evoked intracellular Ca2+ dynamics in magnocellular neurosecretory neurons of hypertensive rats. J Physiol. 2017; https://doi.org/10.1113/JP275169.

Titel: Vasopressin, Central Autonomic Control and Blood Pressure Regulation
verfasst von: Maja Lozić
Olivera Šarenac
David Murphy
Nina Japundžić-Žigon
Publikationsdatum: 01.02.2018
Verlag: Springer US
Erschienen in: Current Hypertension Reports / Ausgabe 2/2018
Print ISSN: 1522-6417
Elektronische ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-018-0811-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Vasopressin, Central Autonomic Control and Blood Pressure Regulation

Abstract

Purpose of Review

Recent Findings

Summary

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

Integrative Physiological Aspects of Brain RAS in Hypertension

Cardiovascular Risk in Patients with Prehypertension and the Metabolic Syndrome

Angiotensin-(1–7) and Alamandine on Experimental Models of Hypertension and Atherosclerosis

Hypothalamic Ion Channels in Hypertension

The Global Epidemic of the Metabolic Syndrome

New Developments in Hypertensive Encephalopathy

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Hinter dieser Appendizitis steckte ein Erreger

Demenzkranke durch Antipsychotika vielfach gefährdet

Update Innere Medizin